This venture capital firm invests in early-stage companies addressing high unmet patient needs, primarily in life sciences and healthcare sectors.
Helsinn Investment Fund S.A. is a Luxembourg fund focused on early-stage investments in areas of high unmet patient need.
Key people at 3B Future Health Ventures (Helsinn Investment Fund).
3B Future Health Ventures (formerly Helsinn Investment Fund) is a venture capital firm dedicated to advancing healthcare innovation by investing in early-stage companies that address high unmet patient needs. The fund’s mission centers on accelerating the development of novel therapies and technologies in life sciences and healthcare, with a strong emphasis on improving patient outcomes. Its investment philosophy prioritizes companies with robust scientific foundations, ideally with preclinical or early clinical proof of concept, and experienced management teams. The firm targets sectors including cancer therapeutics and diagnostics, supportive care, metabolic and gastrointestinal disorders, and dermatology, supporting both biotech and medtech startups. By combining capital with strategic guidance, operational support, and board-level involvement, 3B Future Health Ventures plays a catalytic role in nurturing the next generation of healthcare innovators.
Founded in 2016 as the Helsinn Investment Fund, the firm was established by the Helsinn Group, a Swiss pharmaceutical company with a 40-year legacy in cancer care and patient-focused innovation. The fund was launched as part of Helsinn’s broader strategy to expand its impact beyond traditional drug development, leveraging its deep industry expertise to support early-stage ventures. The transition to 3B Future Health Ventures marked a strategic evolution, broadening its scope and reinforcing its commitment to fostering innovation across the healthcare ecosystem. The fund is fully owned by Helsinn Group and operates out of Luxembourg, with a global outlook and a focus on building partnerships with startups in the U.S., Europe, and Israel.
3B Future Health Ventures is riding the wave of increased demand for innovative healthcare solutions, particularly in oncology and rare diseases. The timing is critical, as advances in biotechnology, diagnostics, and digital health are creating new opportunities to address unmet medical needs. Market forces such as rising healthcare costs, an aging population, and the growing importance of personalized medicine are working in the fund’s favor. By supporting early-stage companies, 3B Future Health Ventures helps bridge the gap between scientific discovery and clinical application, influencing the broader ecosystem by fostering collaboration, accelerating innovation, and driving the development of new therapies.
Looking ahead, 3B Future Health Ventures is well-positioned to continue its impact as a leading investor in healthcare innovation. The firm’s deep industry expertise, global network, and commitment to patient-centric solutions will be key drivers of its future success. Trends such as the rise of precision medicine, the integration of AI in drug discovery, and the increasing focus on rare diseases are likely to shape the fund’s investment strategy. As the healthcare landscape evolves, 3B Future Health Ventures will play a pivotal role in shaping the future of patient care, supporting startups that are poised to make a meaningful difference in the lives of patients worldwide.
Key people at 3B Future Health Ventures (Helsinn Investment Fund).
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2025 | Fore Biotherapeutics | $40.0M Series D | — | Roberto De Ponti, Hbm Partners, Novartis Venture Fund, Pontifax Venture Capital, SR One |
| Sep 1, 2024 | Epsilogen | $16.0M Series B | — | Marianne Bjørdal, Albion VC, Novartis Venture Fund |
| Aug 1, 2023 | Fore Biotherapeutics | $75.0M Series D | — | Roberto De Ponti, Hbm Partners, Novartis Venture Fund, Pontifax Venture Capital, SR One |
| Apr 1, 2023 | Geneos Therapeutics | $5.0M Series A | — | Seventure Partners |
| Oct 1, 2022 | Sibylla Biotech | $23.0M Series A | — | Marianne Bjørdal, Claris Ventures, Seroba Life Sciences |
| May 1, 2022 | Domain Therapeutics | $41.0M Series A | — | Roberto De Ponti, Seventure Partners |
| Mar 1, 2022 | Epsilogen | $41.0M Series B | — | Marianne Bjørdal, Albion VC, Novartis Venture Fund |
| Oct 1, 2021 | GenEp | $1.0M Seed | — | — |
